NUDT15 intermediate metabolisers are associated with lower loss of response in paediatric Crohn’s disease patients treated by combination treatment with infliximab and azathioprine,Alimentary Pharmacology & Therapeutics

当前位置： X-MOL 学术 › Aliment. Pharm. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

NUDT15 intermediate metabolisers are associated with lower loss of response in paediatric Crohn’s disease patients treated by combination treatment with infliximab and azathioprine
Alimentary Pharmacology & Therapeutics ( IF 6.6 ) Pub Date : 2022-01-14 , DOI: 10.1111/apt.16769
Eun Sil Kim ₁ , Sujin Choi ₂ , So Yoon Choi ₃ , Ji Hyung Park ₁ , Byung-Ho Choe ₂ , Soo-Youn Lee ₄ , Mi Jin Kim ₁ , Yon Ho Choe ₁ , Ben Kang ₂

Affiliation

NUDT15 polymorphisms are associated with leukopenia during treatment with thiopurines. However, data regarding its effect on treatment outcomes are scarce.

中文翻译：